Metformin Improves Glucose Effectiveness, Not Insulin Sensitivity: Predicting Treatment Response in Women With Polycystic Ovary Syndrome
Abstract
Although metformin is widely used to improve insulin resistance in women with PCOS, its mechanism of action is complex with inconsistent effects on insulin sensitivity and variability in treatment response. The objective of this open label, interventional study was to delineate the effect of metformin on glucose and insulin parameters, determine additional treatment outcomes, and predict patients with PCOS who will respond to treatment. The subjects of this study were women with PCOS (n=36), diagnosed by the NIH criteria, who underwent fasting blood samples, an intravenous glucose tolerance test (IVGTT), dual-energy X-ray absorptiometry scan, trans-vaginal ultrasound and hCG-stimulated androgen levels before and after 12 weeks of treatment with metformin ER 1500 mg/day. Interval visits were performed to monitor metabolic parameters, anthropomorphic measurements, and ovulatory menstrual cycles. The results of this study showed that after metformin treatment insulin sensitivity did not change despite weight loss. However, glucose effectiveness (p=0.002) and the acute insulin response to glucose (p=0.002) increased and basal glucose levels (p=0.001) and testosterone decreased. Furthermore, women with improved ovulatory function (61%) had lower baseline testosterone levels and lower baseline and stimulated testosterone and androstenedione levels after metformin treatment (all p<0.05). In conclusion, using an IVGTT, which distinguishes improvements in glucose effectiveness and…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.